slides current until 2008 diagnosis, classification and prevention of diabetes section 1 | 1 of 4...

Slides current until 2008

Diagnosis, classification and prevention of diabetes

Section 1 | 1 of 4

Curriculum Module II–1 | Diagnosis, classification and presentation of diabetes


Diagnosis and typesCurriculum Module II-1

Slide 2 of 48

Definition of diabetes

Characterized by hyperglycaemia

• Defects in insulin production

• Autoimmune or other destruction of beta cells

• Insulin insensitivity

• Impaired action of insulin on target tissues



Slide 3 of 48

Definition of diabetes

Chronic hyperglycaemia associated with long-term damage to:

• Eyes

• Kidneys

• Nerves

• Heart and blood vessels



Slide 4 of 48

The diabetes epidemic

• 230 million affected in 2006

• 350 million within 20 years

• Most rapid in Indian and Asian subcontinents

IDF Diabetes Atlas



Slide 5 of 48

Classification

• Type 1 diabetes

–autoimmune

–LADA

–idiopathic

• Type 2 diabetes



Slide 6 of 48

Other specific types

• MODY

• Defects in insulin action

• Diseases of the pancreas

• Endocrine disorders

• Drug- or chemical-induced

• Infections

Classification



Slide 7 of 48

• Uncommon forms of immune-mediated diabetes

• Other genetic syndromes

• Gestational diabetes

Classification



Slide 8 of 48

Insulin

GluconeogenesisGlycogenolysisGlycogen synthesis

Glucose uptakeGlycogen synthesis

Blood glucose

Insulin and glucose disposal

Free fatty acid release



Slide 9 of 48

Glucose uptake Glycogenolysis Gluconeogenesis (amino acids) Ketone production (fatty acids)

Glucose uptake Protein degradation amino acids

Blood glucose

Insulin deficiency in type 1 diabetes

Triglyceride degradation fatty acids



Slide 10 of 48

Glucose uptake

Glycolysis

Gluconeogenesis (amino acids)


Blood glucose

Insulin insensitivity in ttype 2 diabetes



Slide 11 of 48

Blood glucose

Glucose uptake

Insensitivity to insulin inttype 2 diabetes

Glucose uptake

Glycolysis





Slide 12 of 48

Blood glucoseConverted to triglycerides

Effect of insulin resistance in ttype 2 diabetes

Glucose uptake

Glycolysis



Glucose uptake



Slide 13 of 48

Pathogenesis of type 1 diabetes

• Immunological activation

• Progressive beta-cell destruction

• Insufficient beta-cell function

• Dependent on exogenous insulin

• Risk of ketoacidosis



Slide 14 of 48


• Genetic susceptibility

• Immune factors– other autoimmune disease– antigen-specific antibodies

• Environmental trigger– viruses– bovine serum albumin– nitrosamines: cured meats– chemicals: vacor (rat poison),

streptozotin



Slide 15 of 48

Beta-cell mass


Time (months - years)

Trigger

Genetic

Pre-diabetes ‘Honeymoon’

Chronic phase

Clinical diabetes

Immunological abnormalities



Slide 16 of 48

Idiopathic type 1 diabetes

Non-autoimmune type 1 diabetes

• No autoimmune markers

• Permanent insulinopenia

• Ketoacidosis

• People of African and Asian origin



Slide 17 of 48

Epidemiology of type 1 diabetes

• Increasing in recent years

• Geographic variation

• Relative affluence

• Lack of treatment

IDF Diabetes Atlas



Slide 18 of 48

• Age of onset peaks

– preschool

– puberty

• Autumn/winter peaks




Slide 19 of 48

Type 2 diabetes

• 90%-95% of people with diabetes

• Insulin insensitivity and relative insulin deficiency

• Obesity or overweight

• Complications often present at diagnosis



Slide 20 of 48


• Multiple genes involved

• Hyperinsulinaemia

• Poor fetal nutrition beta-cell formation

• Low birth weight/weight change

• “Thrifty gene”

• 7% beta-cell loss



Slide 21 of 48

Age (years)

Endogenous insulin

Insulin requirements

Beta-cell loss

The natural history of type 2 diabetes

Insulin requirements with age

Primary failure



Slide 22 of 48

Age (years)

Endogenous insulin


Beta-cell loss

Insulin insensitivity

Hyper-insulinaemia





Slide 23 of 48

Age (years)

Endogenous insulin


Secondary failure


Effect of oral drugs


Beta-cell loss

Hyper-insulinaemia

Insulin insensitivity



Slide 24 of 48


• Dramatic increase

• Aging population

• Disturbing trends parallel obesity epidemic

• Especially in adolescents and minority groups

• Increasing in young people



Slide 25 of 48ACTIVITY

• What are the most common risk factors for type 2 diabetes for people in your country?

• Are any of these risk factors modifiable?



Slide 26 of 48

Risk factors for type 2 diabetes

• Age > 40 years

• First-degree relative with diabetes

• Member of high risk population

• History of impaired glucose tolerance, impaired fasting glucose

• Vascular disease

• History of gestational diabetes

• History of delivery of macrosomic baby

CDA 2003



Slide 27 of 48

• Hypertension

• Dyslipidaemia

• Abdominal obesity

• Overweight

• Polycystic ovary disease

• Acanthosis nigricans

• Schizophrenia

Risk factors for type 2 diabetes



Slide 28 of 48

• Polydipsia

• Polyuria

• Nocturia

• Visual disturbance

• Fatigue

• Weight loss

• Infections

Signs and symptoms



Slide 29 of 48

Diagnosing diabetes

Normal Impaired fasting glucose*

Impaired glucose tolerance**

Diabetes

FPG <6.1mmol/L

<110mg/dL

6.1 to 6.9mmol/L*

110 to 126mg/dL

≥7.0mmol/L

≥126mg/dL

2hr PG <7.8mmol/L

<126mg/dL

7.8 to 11mmol/L**

126 to 200mg/dL

≥11.1mmol/L

≥200mg/dL

CDA 2003, ADA 2004, WHO 2002



Slide 30 of 48

Impaired glucose toleranceImpaired fasting glucose

• Intermediate states

• Increased risk of developing diabetes

• Prevention strategies to prevent or delay progression

• Increased risk of cardiovascular disease



Slide 31 of 48

Uncertain diagnosis:Oral glucose tolerance test

• 75 g glucose load after 8 hours fasting

• Readings taken in fasting state and at 1 and 2 hours

• Possible problems



Slide 32 of 48

• Urinary ketones

• Antibodies

• C-peptide

Tests for differential diagnosis



Slide 33 of 48

Metabolic syndrome

• Cluster of risk factors or syndrome

• Type 2 diabetes

• Different criteria

• Three-fold increase in heart disease and stroke

• Two-fold increase in cardiovascular disease deaths



Slide 34 of 48

Prevention of type 1 diabetes

• Early exposure to cows milk protein

• Nicotinamide



Slide 35 of 48


Insulin

• Diabetes Prevention Trial

• Diabetes Prediction and Prevention Project



Slide 36 of 48


Lifestyle modification

• Da Qing Study

• Finnish Diabetes Prevention Study



Slide 37 of 48


Lifestyle vs medication

• Diabetes Prevention Program

• STOP-NIDDM



Slide 38 of 48ACTIVITY

Type 2 diabetes can be delayed in people with IGT

Lifestyle modification is most effective

What do you think could be done at community level to prevent or delay diabetes?



Slide 39 of 48

Summary

Type 1 diabetes

• Results from progressive beta-cell destruction

• People with type 1 diabetes need insulin therapy to live



Slide 40 of 48

Type 2 diabetes

• Often characterized by insulin insensitivity and relative rather than absolute insulin deficiency

• A progressive condition

• Most people with type 2 diabetes will need insulin within 5 to 10 years of diagnosis

Summary



Slide 41 of 48

Review question

1. The pathogenesis for type 2 diabetes includes:

a. Insulin deficiency and insulin insensitivity

b. Insensitivity to insulin and autoimmune beta-cell destruction

c. Autoimmune beta-cell destruction and glucagon deficiency

d. Insulin deficiency and glucagon deficiency



Slide 42 of 48

Review question

2. A person with type 2 diabetes, recently started on insulin, asks if there is a way to measure if he/she is still producing any insulin. The correct response would be:

a. Islet cell antibody tests

b. C-peptide test

c. HbA1c test

d. Serum insulin test



Slide 43 of 48

Review question

3. The Diabetes Prevention Program (DPP):

a. Included people with type 1 diabetes

b. Included only people with IGT

c. Tested the value of exercise

d. Included people with type 2 diabetes



Slide 44 of 48

Review question

4. Type 1 diabetes is usually caused by:

a. Injury to the pancreas

b. An autoimmune reaction

c. Insulin insensitivity in the cells

d. Hypersensitivity to insulin



Slide 45 of 48

Answers

1. a

2. b

3. b

4. b



Slide 46 of 48

References

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(suppl 1): S5-S10.

2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab 2003; 27(suppl 2).

3. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomized trial. Lancet 2002; 346: 393-403.

4. Delahanty LM and Halford BN. The role of Diet Behaviours in Achieving improved glycaemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care 1993; 16(11): 1453-58.

5. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin dependent diabetes mellitus: Diabetes Control and Complications Trial. The Journal of Paediatrics 1994; 125(2): 177-88.

6. Diabetes Control and Complications Trial/epidemiology of diabetes interventions and complications research group intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. New Engl J Med 2003; 348: 2294-303.

7. Diabetes Control and Complications Trial: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.



Slide 47 of 48

References

8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 297: 356-59.

9. Diabetes Atlas 2006. Brussels: International Diabetes Federation, 2006.

10. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24(4): 683-9.

11. Pan X, Li G, Hu Y, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20(4): 537-44.

12. Report of a WHO Consultation. Laboratory Diagnosis and monitoring of Diabetes Mellitus. World Health Organisation 2002. http://whqlibdoc.who.int/hq/2002/9241590483.pdf cited April 30, 2005.

13. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 2001; 344: 1343-50.

14. The Diabetes Prevention Program Research Group. The diabetes prevention Program (DPP). Diabetes Care 2002; 23(12): 2165-71.

15. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulpfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.



Slide 48 of 48

References

16. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38. BMJ 1998; 317: 703-13.

17. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.

18. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic Control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diab Research and Clin Pract 2005; 70: 90-7.

slides current until 2008 diagnosis, classification and prevention of diabetes section 1 | 1 of 4...

Documents

presentation of diabetes

types curriculum module

slides current

mediated diabetes

diabetes epidemic

classification type

prevention of diabetes

t type